ENTITY
Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics
Crinetics; PALSONIFY; Palsonify; Q4 2025; revenue; $5M; acromegaly; enrollment forms; prescribers
Novo Nordisk Launches Wegovy Pill in the US with Broad Availability
Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss
Argenx Appoints Karen Massey as New CEO in Leadership Transition
argenx; Karen Massey; CEO; Tim Van Hauwermeiren; leadership transition; rare diseases; Vyvgart
Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations
Zenas BioPharma; obexelimab; Phase 3 INDIGO; IgG4-related disease; share plunge; Amgen Uplizna
Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026
Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M
Biotech’s Groove is Back for 2026: XBI Surges Amid M&A Boom and Lower Rates
biotech; XBI; M&A; lower rates; 2026 trends
Insilico Medicine and Servier Announce Up to $888 Million AI-Driven Oncology R&D Collaboration
Insilico Medicine; Servier; AI platform; oncology; drug discovery; Pharma.AI; $888 million
FDA Clears BrainSpace Intellidrop: Automated Neuro Device Tackling ICU Nursing Shortages and Advancing Physical AI
FDA clearance; BrainSpace; Intellidrop; ICU nursing shortages; brain fluid management; Physical AI; neuro injury
Orum Therapeutics Appoints Chad May as Chief Scientific Officer
Orum Therapeutics; Chad May; CSO; Degrader-Antibody Conjugates; DAC; Targeted Protein Degradation
Genelux Corporation Appoints Jason Litten, M.D., as Chief Medical Officer to Advance Olvi-Vec Development
Genelux Corporation; Jason Litten; Chief Medical Officer; CMO; Olvi-Vec; immuno-oncology; clinical trials